Page 30 - Unlikely Stories 1
P. 30

DeathCon



        Now,  what  we’ve  done  here  is  analyze  the  nucleotide  bonding
        between layers of telomere, the protective caps on your DNA that
        enable it to copy itself accurately when the cell it occupies divides. In
        normal  circumstances,  those  caps  disintegrate  slowly  over  time—
        that’s  one  reason  we  age:  after  a  certain  number  of  copies,  the
        telomeres end up shortened beyond being able to protect their DNA
        against  transcription  errors,  leading  to  cell  death  and  the
        abnormalities  of  cancer.  You  are  probably  aware  of  the  longevity
        research focusing on telomere preservation.”
               “Uh, no, not really. So how does this Atropos 500 work?”
               “Without getting into the biochemistry, Buell, I can tell you
        my discovery of anti-telomerase, would, under other circumstances,
        be worthy of a Nobel Prize—he was a major armament manufacturer
        as well as a chemist who invented dynamite, you know, but I’m not
        bitter. It is a simple compound patented under the name of Atropos,
        the license owned by Genomonix. It can be sprayed as an aerosol or
        introduced  to  the  food  chain  completely  undetected.  Once  in  the
        bloodstream  it  is  taken  into  the  cells  of  the  body  with  little  or  no
        resistance. There it begins dissolving the linkages holding telomeres
        together. Months will pass before the enemy realizes it is facing an
        epidemic of disease and premature death, none of it apparently the
        direct result of an attack by a hostile power. The ‘500’ refers to the
        number of days it remains stable; after that it decomposes into water
        and CO2, leaving not a trace.”
               “Ooh, that sounds wicked, Jessie. But now that you’ve gone
        public with this, how can you be certain that the enemy won’t realize
        right away that their people have been sabotaged by your diabolical
        molecules?”
               “Oh, Buell, that’s really cute. I don’t know if your naiveté is
        for real—is it? Oh, don’t answer and spoil it for me—but you really
        must  know  that  Genomonix  is  also  working  on  a  test  for  the
        presence of Atropos and an antidote to counter its effects. You see,
        we’ve learned from agribusiness biotech: create the problem and its
        solution, the pesticide and the resistant seed, and sell them both.”



                                       29
   25   26   27   28   29   30   31   32   33   34   35